Weidemann Friederike, Decker Sebastian, Epping Jelena, Örgel Marcus, Krettek Christian, Kühn Christian, Wilhelmi Michaela
Trauma Department, Hannover Medical School, Hannover, Germany.
Medical Sociology Unit, Hannover Medical School, Hannover, Germany.
Int J Artif Organs. 2022 Jan;45(1):81-88. doi: 10.1177/0391398820980736. Epub 2021 Jan 13.
Thoracic trauma is the most common injury in polytrauma patients. Often associated with the development of an acute respiratory distress syndrome (ARDS), conservative treatment options are very restricted and reach their limits quickly.
Extracorporeal membrane oxygenation (ECMO) is a wellestablished therapy in cardio-thoracic surgery and internal medicine intensive care units. The purpose of this study is to analyse the potential benefit of ECMO therapy in ARDS treatment in polytrauma patients.
Retrospective case series.
Level 1 trauma centre, Germany, 04/2011-04/2019.
Nineteen patients with ARDS treated with a veno-venous ECMO system.
This study focused on the time leading to therapy initiation, the severity of thoracic and overall injury. The Sequential Organ Failure Assessment (SOFA) Score, the Murray Score, the Abbreviated Injury Scale (AIS) 2005 level and the Injury Severity Score (ISS) were analysed. The results were analysed regarding survival and death.
The survival rate was 53%. The ISS was the same for survivors and deceased patients ( = 0.604). Early initiation of ECMO therapy showed a significant trend for survivors ( = 0.071). The SOFA Score level before ECMO therapy was significantly lower in the survivors than in those who died ( = 0.035). The AISThorax level for survivors showed a significantly higher score level than the one for deceased patients ( = 0.05).
ECMO therapy in polytrauma patients is a safe and effective option, in particular when used early in ARDS treatment. The overall severity of organ failure determined the likelihood of survival rather than the thoracic trauma itself.
胸部创伤是多发伤患者中最常见的损伤。常与急性呼吸窘迫综合征(ARDS)的发生相关,保守治疗选择非常有限且很快就会达到极限。
体外膜肺氧合(ECMO)是心胸外科和内科重症监护病房中一种成熟的治疗方法。本研究的目的是分析ECMO治疗在多发伤患者ARDS治疗中的潜在益处。
回顾性病例系列研究。
德国一级创伤中心,2011年4月至2019年4月。
19例接受静脉-静脉ECMO系统治疗的ARDS患者。
本研究重点关注开始治疗的时间、胸部和全身损伤的严重程度。分析了序贯器官衰竭评估(SOFA)评分、默里评分、简明损伤量表(AIS)2005版级别和损伤严重程度评分(ISS)。对生存和死亡结果进行了分析。
生存率为53%。幸存者和死亡患者的ISS相同(P = 0.604)。早期开始ECMO治疗在幸存者中显示出显著趋势(P = 0.071)。幸存者在ECMO治疗前的SOFA评分水平显著低于死亡患者(P = 0.035)。幸存者的AIS胸部级别评分显著高于死亡患者(P = 0.05)。
多发伤患者的ECMO治疗是一种安全有效的选择,特别是在ARDS治疗早期使用时。器官衰竭的总体严重程度决定了生存的可能性,而不是胸部创伤本身。